Compositions and methods for chemical synthesis
Patent Information
- Application Number
- JP2023531528
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-25
- Filing Date
- 2021-11-09
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2041-11-09
AI Technical Summary
Current methods for solution-phase peptide synthesis, such as Fmoc/tBu chemistry, face challenges in scalability, efficiency, and cost due to the use of expensive reagents like 4-aminomethylpiperidine and limitations with traditional C-terminal protecting groups like HOBnDpp, which are not acid-labile and require separate cleavage steps, making them unsuitable for large-scale production and C-terminal modifications.
The development of novel Group Assisted Purification (GAP) chemistry using novel GAP molecules like HOBnDpp, NH2PhDpp, and RAG, which provide stable C-terminal protection, allowing for solubility control and one-step global deprotection, enabling efficient synthesis of longer peptides with C-terminal modifications in a cost-effective manner.
This approach enhances solubility control during peptide synthesis, reduces the need for additional purification steps, and allows for scalable production of peptides with C-terminal modifications, overcoming the limitations of traditional methods by providing stable and economically viable C-terminal protection.
Smart Images

Figure 2022115825000001 
Figure 2022115825000002 
Figure 2022115825000003
Abstract
Description
[Technical field]
[0001] Any and all applications (whether filed herewith or subsequently amended) in which a foreign or domestic priority claim is identified in an Application Data Sheet are hereby incorporated by reference under 37 CFR § 1.57. This application cross-references: i) PCT Application No. PCT / US16 / 68112, filed December 21, 2016, entitled "System and method for solution phase GAP peptide synthesis," ii) PCT Application No. PCT / US19 / 29569, filed April 29, 2019, entitled "Method for Solution-Phase Peptide Synthesis," iii) PCT Application No. PCT / US19 / 33296, filed May 21, 2019, entitled "Method for Solution-Phase Peptide Synthesis and Protecting Strategies Thereof," and iv) PCT Application No. PCT / US20 / 15132, filed January 26, 2020, and each of these applications is incorporated herein by reference in its entirety. This application is described in PCT / US19 / 33296, PCT / US20 / 15132, U.S. Patent Application No. 62 / 678,564, and U.S. Patent Application No. 62 / 800,142, which are incorporated herein by reference in their entirety.
[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT none
[0003] Sequence Listing, Table, or Computer Listing Reference to a Compact Disc Appendix none [Background technology]
[0004] Recent research efforts have made great advances in the field of purification chemistry, especially focusing on avoiding column chromatography and recrystallization. This work is defined as group-assisted purification (GAP) chemistry / technology, as chemistry for organic synthesis that avoids traditional purification methods such as chromatography and / or recrystallization by deliberately introducing well-functionalized groups into starting materials or newly generated products. These GAP groups are also often used as protecting groups to prevent undesired side reactions during the synthesis of target molecules. Such work has the potential to encompass the entire field of synthetic organic chemistry.
[0005] Protecting groups are found in almost all complex syntheses where multiple functional groups are present. For GAP chemistry, an ideal example would be one where a semi-permanent protecting group introduces the necessary solubility properties for GAP. However, many of the traditional protecting groups are non-polar and therefore do not provide the necessary solubility for GAP in most substrates. If a protecting group with suitable solubility control could be developed, it could potentially extend GAP chemistry to all syntheses requiring the use of that protecting group. Several methods have been utilized. Published patent application WO 2014093723 A2 teaches protecting imines with a chiral auxiliary equipped with GAP and using these chiral N-phosphonylimines as electrophiles in asymmetric boron addition reactions. Purification was performed by the GAP method. This work is valuable in that chiral α-boronic acid amines can be easily obtained and potentially used to synthesize novel amino acid derivatives and incorporate them into novel peptide targets.
[0006] Effective protecting groups need to be robust to a wide variety of conditions and be added and removed in high yields. Protecting groups are used extensively in peptide synthesis, either by solid-phase or solution-phase methods. In traditional peptide synthesis protection strategies, one of the most commonly used strategies is Fmoc / tBu. US Patent No. 8,383,770 B2 teaches the use of fluorenylmethoxycarbonyl (Fmoc) and tert-butyloxycarbonyl (Boc) N-terminal protecting groups in solid-phase peptide synthesis (SPPS). This technology is well known and widely applied in industry. The Fmoc group protects the N-terminus of the amino acid that is added to the growing peptide, and tert-butyl (tBu)-based groups protect the side chain of the same amino acid. The Fmoc group can be removed with an appropriate deprotecting agent, and the tBu group remains until global acid deprotection at the end of the synthesis. The Boc and Fmoc groups have been used in all areas of peptide chemistry for decades, with the preferred Fmoc group being almost exclusive to SPPS.
[0007] SPPS, developed by Merrifield in the 1960s, has become a standard protocol used in multiple scientific disciplines for research and manufacturing (see Figure 1A). The advantage of polymeric supports or resins lies in the ability to easily purify the growing peptide after each coupling / deprotection step, thus avoiding the use of column chromatography. The main disadvantage of SPPS lies in the difficulty of scaling up, as many polymeric supports are expensive and represent a large proportion of the mass of material to be handled. Also, the coupling reaction in SPPS is inefficient, since it is carried out at a solid-liquid interface. Moreover, after each deprotection and coupling reaction, the resin must be washed with solvent to remove impurities from the previous reaction, which generates significant solvent waste, which is very problematic at large scale.
[0008] However, examples of economically feasible Fmoc protection schemes for solution phase peptide synthesis (SolPPS) are rare and almost completely absent in the literature. US Patent No. 5,516,891A provides one of the few examples of Fmoc-based SolPPS. Again, Fmoc peptide synthesis is mostly limited to SPPS due to the by-product N-fluorenylmethylpiperidine (NFMP) generated during deprotection, which is difficult to remove without a polymeric support. The standard protocol for Fmoc deprotection is to stir the Fmoc-peptide with excess piperidine in a solution of dimethylformamide (DMF) or dichloromethane (DCM), deprotecting the Fmoc group and forming NFMP in the process. The '891 patent teaches removing this impurity by deprotecting with 4-aminomethylpiperidine (4AMP) instead of piperidine. This results in the formation of NFMP-CH2NH2 instead of NFMP, which can be extracted into water due to the presence of an extra amino group. The problem with this method is the high cost associated with using 4AMP, which makes this method expensive and has not been accepted in the industry.
[0009] Another example of Fmoc-based SolPPS can be found in published patent application WO2017112809A1. This publication teaches the use of a C-terminal GAP protecting group, benzyldiphenylphosphine oxide (HOBnDpp), to control the solubility of the target peptide so that it can be selectively precipitated after each successive coupling reaction (see Figure 1B). Solubility is controlled so that the growing peptide remains in an organic solvent, such as ethyl acetate or DCM, and water washes are performed to remove impurities. The organic solvent is then concentrated and mixed with an alkane solvent, and the peptide product selectively precipitates. Although this technique has adapted Fmoc / tBu chemistry to the solution phase in a much more economically feasible manner than the '891 patent, potential limitations are inherent to the method. First, the GAP group is not acid labile, precluding one-step global deprotection with the commonly used trifluoroacetic acid (TFA) system or other acid mixtures, and hydrogenation or hydrolysis is required to remove HOBnDpp from the peptide's C-terminus. Furthermore, as peptides continue to grow and sequence changes occur, HOBnDpp becomes less and less able to maintain control over solubility as the chain lengthens or as the sequence confers different solubility properties to the peptide. HOBnDpp is also susceptible to hydrolysis and accidental cleavage during synthesis. For example, during deprotection of the second amino acid in a peptide sequence with Fmoc, the formation of diketopiperazine (DKP) can easily cause loss of HOBnDpp from the C-terminus. This cleaved HOBnDpp remains in the reaction solution and reacts with activated amino acids during coupling reactions to generate impurities that are difficult or impossible to remove. Furthermore, with current cleavage techniques (either hydrolysis or hydrogenation) to deprotect the C-terminus after synthesis of a protected peptide, the C-terminus of the final peptide product is a carboxylic acid. Conversely, many therapeutic peptides require modification of the C-terminus to amides, cyclic peptides, thioesters, etc., instead of this carboxylic acid, further limiting the applicability of the GAP peptide synthesis method. Furthermore, these cleavage reactions to remove HOBnDpp from the C-terminus are separate reactions from the global deprotection, which require specific conditions and workup, and are both time-consuming and costly.
[0010] Due to these and other issues with scale-up in SPPS, as well as limitations in existing GAP peptide synthesis protection strategies, there is a need in the industry not only for SolPPS methods that are amenable to scale-up, but also for SolPPS methods that are more amenable to (i) a range of cleavage conditions, (ii) longer or more difficult sequences (from a solubility standpoint), and (iii) C-terminal modifications. Summary of the Invention
[0011] In one embodiment, the present disclosure can include a chemical composition that includes a GAP moiety, a spacer moiety, and a linker moiety, where the spacer moiety is disposed between the GAP moiety and the linker moiety.
[0012] In another embodiment, the disclosure can include a method for synthesizing a peptide, the method comprising the steps of: attaching a first amino acid to an anchor molecule, the anchor molecule comprising a GAP moiety and a linker moiety, the first amino acid being attached to the linker moiety of the anchor molecule, forming a peptide bond between a second amino acid and the first amino acid, and removing the anchor molecule from the first amino acid. In another embodiment, the disclosure can include a method of forming a composition comprising a GAP anchor, the method comprising the steps of providing a GAP moiety and attaching the GAP moiety to the linker moiety.
[0013] In another embodiment, the disclosure may include a method for synthesizing a peptide, the method comprising attaching a GAP anchor to a first amino acid, forming a peptide bond between a second amino acid and the first amino acid, and removing the GAP anchor from the first amino acid, wherein the GAP anchor is Compound 1 (wherein n=2 or 9) [ka] , compound 2 [ka] , compound 3 [ka] , Compound 4 (wherein R=H, Me, Et, or iPr) [ka] , Compound 5 (wherein n=0 or 2) [ka] , Compound 6 (wherein n=0 or 2 and Y=O, NMe, NEt, or N-iPr) [ka] , Compound 7 (wherein n=0 or 2) [ka] , Compound 8 (wherein n=0 or 2 and Y=O, NMe, NEt, or N-iPr) [ka] , compound 9 [ka] , Compound 10 (wherein n=0 or 2) [ka] and compound 11, where n=0 or 2. [ka] is selected from the group consisting of: The above and other objects, features, and advantages of the present disclosure will become apparent from the following description of embodiments illustrated in the accompanying drawings, in which reference characters refer to the same parts throughout the various views. The drawings are not necessarily to scale, emphasis instead being placed on illustrating the principles of the present disclosure. The figures are used as non-limiting examples and are intended only to depict preferred embodiments, without limiting the scope of the present disclosure. [Brief description of the drawings]
[0014] [Figure 1A] FIG. 1A depicts a prior art method of solid phase peptide synthesis (SPPS). [Figure 1B] FIG. 1B shows the steps of the GAP peptide synthesis (GAP-PS) method, specifically depicting the use of HOBnDpp for C-terminal protection. [Diagram 2] FIG. 2 depicts a method for attaching the protecting group of FIG. 1B to the side chain of an amino acid residue, specifically, in this non-limiting embodiment, a serine, followed by GAP-PS. [Diagram 3] FIG. 3 depicts, as an example, a schematic for synthesizing and attaching a novel GAP molecule to a peptide, in which HOBnDpp is reacted with a protected Rink Amide-OH and the resulting novel chemical entity Rink Amide-GAP (RAG) is attached to the C-terminus of an amino acid. [Figure 4] Figure 4 depicts the attachment of novel GAP molecules to the side chains of amino acids. In this non-limiting example, the GAP molecule RAG is used to protect the side chain of aspartic acid to synthesize RAG-protected asparagine. Specifically, a coupling reaction is carried out to form an amide bond between the free amine on the RAG molecule and the carbonyl carbon of asparagine. [Diagram 5]5 depicts a non-limiting example of the synthesis of novel GAP molecules. In this non-limiting example, HOBnDpp is linked directly to protected HMPA-OH to form HMPA-GAP(HG), as well as through an intermediate (in one embodiment, phenylalanine) to form the GAP molecule HMPA-phenylalanineGAP(HPG). Specifically, HOBnDpp can be attached to the carboxylic acid moiety of protected HMPA-OH, or HOBnDpp can be attached first to an amino acid and then to HMPA to form the GAP molecule HPG. [Figure 6] Figure 6 depicts the attachment of HPG from Figure 5 to the C-terminus of a generic amino acid, as well as, in a preferred embodiment of the present disclosure, to the side chain of aspartic acid. Specifically, this reaction is a coupling reaction that can be accomplished by the use of several different coupling reagents, in which the free alcohol of HPG combines with the carbonyl group of an activated carboxylic acid. [Figure 7] FIG. 7 depicts a non-limiting example of the synthesis of a novel GAP molecule, anilinediphenylphosphine oxide ("NH2PhDpp"). [Figure 8] 8 depicts a non-limiting example of the synthesis of a novel GAP molecule, in which NH2PhDpp is reacted with a protected Rink Amide-OH to achieve the target entity. Specifically, NH2PhDpp can be coupled to the carboxylic acid moiety of the protected Rink Amide-OH via a number of coupling reagents. [Figure 9] 9 shows a non-limiting example of the synthesis of a novel GAP molecule, in which NH2PhDpp reacts with a protected HMPA-OH, either directly or via an intermediate, to form the target molecule. Several different coupling reagents can be used to facilitate these reactions. [Figure 10] FIG. 10 shows, as a non-limiting example, the compound that results from attaching an HPG GAP molecule to the C-terminus of an Fmoc-protected leucine. [Figure 11]FIG. 11 depicts, as a non-limiting example, compounds resulting from side chain protection of glutamic acid using HPG, where the C-terminus of glutamic acid is protected with an allyl group as a non-limiting example of a possible C-terminal protection strategy. [Figure 12] FIG. 12 shows, as a non-limiting example, the tetrapeptide Fmoc-Glu(HPG)-Glu(HPG)-Tyr(tBu)-Leu-HPG, obtained from the novel SolPPS method disclosed herein. [Figure 13] FIG. 13 depicts the resulting compound where RAG is attached to the side chain of an amino acid, specifically aspartic acid in this non-limiting example, and as a non-limiting example of a C-terminal protection strategy, the C-terminus of the aspartic acid is protected with an allyl group. [Figure 14] FIG. 14 shows, by way of non-limiting example, protected peptides resulting from the SolPPS method disclosed herein. [Figure 15] FIG. 15 shows, as a non-limiting example, the peptide bivalirudin fully protected with a novel GAP molecule. [Figure 16] FIG. 16 shows fully deprotected Bivalirudin, achieved by Fmoc deprotection followed by one-step global protection to remove all side chain and C-terminal protecting groups. [Figure 17] Figure 17 shows the general methodology for protecting amines with novel GAP molecules. In this particular non-limiting embodiment, HPG is used. [Figure 18] FIG. 18 illustrates, by way of non-limiting example, the myriad of molecules that can serve as reagents for the synthesis of the novel GAP molecules disclosed herein. [Figure 19] FIG. 19 shows a number of representative coupling reactions for synthesizing the novel GAP molecules disclosed herein. [Figure 20A] 20A to 20F show the structures of the H-Anchor molecule and its Gap, Linker and Spacer components. [Figure 20B]20A to 20F show the structures of the H-Anchor molecule and its Gap, Linker and Spacer components. [Figure 20C] 20A to 20F show the structures of the H-Anchor molecule and its Gap, Linker and Spacer components. [Figure 20D] 20A to 20F show the structures of the H-Anchor molecule and its Gap, Linker and Spacer components. [Figure 20E] 20A to 20F show the structures of the H-Anchor molecule and its Gap, Linker and Spacer components. [Figure 20F] 20A to 20F show the structures of the H-Anchor molecule and its Gap, Linker and Spacer components. [Figure 21A] 21A and 21B depict exemplary structures of GAP anchor or H-Anchor molecules according to the present disclosure. [Figure 21B] 21A and 21B depict exemplary structures of GAP anchor or H-Anchor molecules according to the present disclosure. [Figure 22] FIG. 22 depicts an exemplary structure of a GAP anchor (H-Anchor) according to an embodiment of the present disclosure. [Figure 23A] 23A and 23B depict an exemplary method of synthesizing a chemical compound according to an embodiment of the present disclosure. [Figure 23B] 23A and 23B depict an exemplary method of synthesizing a chemical compound according to an embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] Reference is made to specific features of the invention in the above Summary of the Invention, the Detailed Description of the Invention, the following claims, and the accompanying drawings. It is to be understood that the disclosure of the invention herein includes all possible combinations of such specific features. For example, when a specific feature is disclosed in connection with a particular aspect or embodiment of the invention, or in a particular claim, that feature can also be used, to the extent possible, in combination with and / or in connection with other specific aspects and embodiments of the invention, and in the invention generally.
[0016] All of the compositions and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that variations can be applied to the compositions and / or methods, and in the steps or sequence of steps described herein, without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
[0017] The term "comprising" and its grammatical equivalents are used herein to mean the optional presence of other components, ingredients, steps, etc. For example, an article "comprising" (or "which comprises") components A, B, and C can consist of (i.e., contain only) components A, B, and C, or it can include not only components A, B, and C, but also one or more other ingredients.
[0018] When reference is made herein to a method that includes two or more defined steps, the defined steps may be performed in any order or simultaneously (unless the context excludes this possibility), and the method may include one or more other steps that are performed before any of the defined steps, between two of the defined steps, or after all of the defined steps (unless the context excludes this possibility).
[0019] In this specification, the term "at least" followed by a number is used to indicate the beginning of a range beginning with that number (which may be a range with an upper limit or a range without an upper limit, depending on the variable being defined). For example, "at least 1" means 1 or greater than 1. In this specification, the term "up to" followed by a number is used to indicate the end of a range ending with that number (which may be a range with a lower limit of 1 or 0 or a range without a lower limit, depending on the variable being defined). For example, "up to 4" means 4 or less than 4, and "up to 40%" means 40% or less than 40%. In this specification, when "(initial value) to (to) (subsequent value)" or "(initial value) to (-) (subsequent value)" is written, it means a range in which the lower limit is the initial value and the upper limit is the subsequent value. For example, 25 to 100 mm means a range with a lower limit of 25 mm and an upper limit of 100 mm.
[0020] The term "first" is used to distinguish one element from another and is not meant to indicate that an element is the primary or first element in any given sequence of elements. For example, "the first amino acid" does not mean that the amino acid is the first in a sequence of amino acids or the first amino acid to be reacted. Rather, "the first amino acid" merely indicates that the amino acid is separate and distinct from another amino acid, such as the "second amino acid."
[0021] The term "coupling reaction" is generally used to refer to the formation of a bond between two constituent molecules, which may be facilitated by a "coupling reagent." In peptide chemistry, these coupling reactions can occur by many different mechanisms under many different reaction conditions that may entirely depend on the coupling reagent used. For example, a coupling reagent can "activate" a carboxylic acid of a constituent molecule such that the carbonyl carbon becomes susceptible to nucleophilic attack. In a coupling reaction, a water molecule may be lost in forming the bond between the two constituent molecules.
[0022] In many types of protection schemes for peptide synthesis, a similar series of reactions occurs to grow the peptide chain. Generally, either the N-terminus or the C-terminus of each amino acid to be added to the chain is first protected, and the other end of the amino acid is free to participate in a coupling reaction. After addition to the chain via the originally unprotected end, a deprotection reaction is performed to free the protected N-terminus or C-terminus to participate in a subsequent coupling reaction to make a peptide bond with the next amino acid. For example, in Fmoc / tBu-based peptide synthesis, the N-terminus of an amino acid is protected with an Fmoc group, and the side chain of the amino acid is protected with a tBu-based protecting group, including but not limited to butyl, trityl (triphenylmethyl), Boc (butyloxycarbonyl), Pbf (2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl), Pmc (2,2,5,7,8-pentamethylchroman-6-sulfonyl), and Acm (acetamidomethyl) (some amino acids do not require side chain protection because the side chain is naturally inert to coupling and deprotection conditions). The C-terminus of the primary amino acid in the peptide sequence is connected and protected to a resin or polymer in SPPS or to a protecting group in SolPPS. The Fmoc / tBu peptide synthesis scheme is designed because the Fmoc group on the N-terminus of the amino acid is base-labile, and treatment with an appropriate deprotecting agent removes the Fmoc group from the N-terminus without interfering with the connection of the C-terminus or the protection of the side chain. Once the deprotection reaction has been carried out, the N-terminus of the first amino acid is free, and the C-terminus and side chain are either protected or naturally inactivated. The next amino acid, whose N-terminus is protected with Fmoc and whose side chain is either protected or naturally inactivated, is then activated at its free C-terminus using a coupling reagent, which promotes nucleophilic attack at the activated carbonyl by the free N-terminus of the first amino acid to form a peptide bond between the first and next amino acids. This process is repeated until the appropriate peptide sequence is obtained. After Fmoc deprotection of the final amino acid, the peptide is still protected at its C-terminus and side chain.Global deprotection with strong acid mixtures, such as TFA-based mixtures, can then be performed to remove all side chain protecting groups and, in some cases, also cleave the resin or protecting group at the C-terminus.
[0023] The present disclosure addresses the shortcomings of the art by providing a method for solution-phase peptide synthesis that allows for a variety of global deprotection strategies, synthesis of longer or more difficult (solubility wise) peptide sequences, and C-terminal modifications on target peptides while maintaining solubility control of the target peptide and the entire synthesis process. By utilizing a new protection strategy for the C-terminus and side chains of the growing peptide, we present a SolPPS strategy that is economically feasible and useful for commercial production of peptides.
[0024] Thus, it is a non-limiting objective of the present disclosure to enable novel methods of SolPPS. In one aspect, the traditional C-terminal GAP protecting group, HOBnDpp, is used to directly protect the side chains of amino acid residues, including but not limited to serine, threonine, tyrosine, or cysteine, instead of or in addition to the C-terminus of the peptide chain. Other amino acid residues of the desired peptide can be protected using a number of different protection strategies, including but not limited to Fmoc / tBu, Boc / benzyl, Cbz (benzyloxycarbonyl) / tBu, Cbz / benzyl, and the like. This enhanced protection strategy allows for the synthesis of longer and / or more challenging sequences while maintaining solubility control of the peptide chain. This strategy also allows for the use of different C-terminal protecting groups for the purposes of solubility, deprotection, or post-synthesis C-terminal modification. In another aspect, the novel GAP molecules described below are used to protect the C-terminus and / or side chains of specific amino acids, allowing for C to N peptide synthesis in solution.
[0025] In another aspect, the novel SolPPS method is achieved by a specially designed C-terminal protection strategy, where the novel GAP molecule protecting groups maintain the advantages of the original GAP peptide synthesis (GAP-PS) while allowing a wider range of cleavage conditions, synthesis of longer peptides, minimal unintended or accidental deprotection, and modification of the C-terminus upon cleavage. Depending on the GAP molecule used, deprotection of the C-terminus can be achieved using acidic conditions including, but not limited to, treatment with trifluoroacetic acid (TFA), hydrofluoric acid (HF), toluenesulfonic acid (TsOH), methanesulfonic acid (MsOH), etc., and basic hydrolysis conditions including, but not limited to, metal hydroxides in either aqueous or alcoholic systems, or biphasic systems using phase transfer catalysis and Pd 0 Or Pt 0 This can be achieved by either molecular hydrogen over a transition metal catalyst such as Ru, transfer hydrogenation, or other hydrogen sources such as borohydride, aluminum hydride, silane, ammonium formate, or other reducing conditions, including but not limited to these. Depending on the particular GAP molecule, C-terminal amide formation and other post-synthetic modifications can also be performed upon cleavage of the GAP molecule at the C-terminus, eliminating extra post-synthetic processing steps to produce the desired peptide product. These novel GAP molecules are stable to acid-catalyzed deprotection reactions, as well as hydrogenation and hydrolysis reactions, allowing for increased recovery of the GAP protecting group after peptide synthesis. Furthermore, loss of the C-terminal protecting group during synthesis is also minimized by these novel GAP molecules.
[0026] In another embodiment, any of the novel GAP molecules described above are used to protect the side chains of various amino acids, including but not limited to aspartic acid, cysteine, serine, threonine, lysine, glutamic acid, asparagine, and glutamine, instead of or in addition to the C-terminus of a peptide. This strategy allows for the protection of reactive side chains while simultaneously controlling the solubility of the target peptide.
[0027] In another aspect, methods for synthesizing these novel GAP molecules and their derivatives are presented. As a non-limiting example, HOBnDpp is attached, either directly or through an intermediate, to the carboxylic acid moiety of a linker molecule, an example of which can be seen in Figure 18, and the resulting novel GAP protecting group is then attached to the C-terminus of a peptide. As another non-limiting example, aniline diphenylphosphine oxide (i.e., NH2PhDpp) is coupled to different linkers in a similar manner to provide novel GAP protecting groups that can be used in a similar manner.
[0028] In alternative embodiments, any of these different strategies described above are utilized in different combinations to allow for the best synthesis strategy for a given peptide. As a non-limiting example, when used appropriately, these strategies allow for the synthesis of longer peptides entirely in solution, with C-terminal deprotection and C-terminal amide formation being accomplished along with side chain deprotection in a one-step reaction.
[0029] Therefore, it is a non-limiting objective of the present disclosure to provide a method for SolPPS. In designing this method, it was clear that the method should seek to maintain the advantages of other solution-phase methods such as GAP-PS, such as avoiding the difficult distillation and purification strategies that hinder large-scale production. Enhanced protection strategies will need to be designed to maintain solubility control of the target peptide to allow separation of the product from the impurities of the generated amino acids and deprotection protocols, while also addressing the shortcomings of the art.
[0030] In a non-limiting exemplary embodiment of the present disclosure, the novel SolPPS method can begin with the direct attachment of HOBnDpp to the C-terminus of the first amino acid in a given sequence (see FIG. 1B). Alternatively, or in addition to protecting the C-terminus of the first amino acid with HOBnDpp, attachment of HOBnDpp to the side chain of an amino acid residue, such as, but not limited to, serine, threonine, tyrosine, and / or cysteine, and subsequent incorporation into the growing peptide can also be performed to better control solubility and protect the side chain of specific amino acids (see FIG. 2). To achieve side chain protection with HOBnDpp, HOBnDpp is first reacted with a halogenating agent (e.g., PBr3, POBr3, (COCl)2, SOCl2, etc.) in the presence of a base (e.g., triethylamine, diisopropylethylamine, sodium bicarbonate, etc.) to yield IBnDpp, ClBnDpp, or BrBnDpp, depending on the halogenating agent used. This reaction can be carried out under a variety of conditions, depending on the halogenating agent and base used in the reaction. By way of example, the reaction can be carried out at pressures between 1 and 100 bar, at temperatures between -78°C and 100°C, and in monophasic or biphasic reaction media. This halogenated compound can then be reacted with an amino acid having a primary protecting group (Pg) at the N-terminus and a secondary protecting group (Pg') at the C-terminus to effectively protect the amino acid side chain. Instead of or in addition to protecting the side chain of one or more amino acids to be incorporated into the peptide sequence with GAP, peptide synthesis can be carried out in the C to N direction, where a GAP molecule protects the C-terminus of the peptide, or alternatively, peptide synthesis can be carried out in the N to C direction, where a HOBnDpp or other GAP molecule protects only the amino acid side chain. For N-terminus and side chain protection, a myriad of protection strategies are possible. Potential N- or C-terminal protecting groups can include, but are not limited to, Cbz, Fmoc, Boc, methyl, Bn (benzyl), or any of the GAP molecules discussed herein, and side chain protecting groups can include, but are not limited to, tBu, Acm, trityl, Boc, Pbf, Pmc, Fm (fluorenylmethyl), and any of the GAP molecules discussed herein.
[0031] In another non-limiting exemplary embodiment, the novel SolPPS method begins with the use of a novel GAP molecule (here, RAG) for C-terminal protection, which may allow both C-terminal protection of acid-labile peptides and C-terminal amide formation upon cleavage of the RAG from the peptide, as seen in Figure 3. Once C-terminal protection with RAG is achieved, peptide synthesis proceeds in a C to N direction and a myriad of N-terminal and side chain protection strategies can be utilized, including but not limited to the Fmoc / tBu strategy. To synthesize RAGs, HOBnDpp can be coupled to protected Rink via a number of coupling reagents, including, but not limited to, TFFH ("N-((dimethylamino)fluoromethylene)-N-methylmethanaminium hexafluorophosphate"), TBTU ("1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole-3-oxide tetrafluoroborate"), HBTU ("1-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazole 3-oxide hexafluorophosphate"), EDCI ("3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine"), or COMU ("(1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate"). Amide-OH to provide the GAP molecule RAG. The coupling reaction can be carried out under a variety of conditions depending on the particular coupling reagent used. As an example, the reaction can be carried out at ambient pressure and room temperature with TBTU with gentle agitation. Once the protected RAG molecule is synthesized, a deprotection reaction (e.g., Fmoc deprotection) can occur to free the amine on the Rink Amide to participate in coupling reactions with carboxylic acids such as those present at the C-terminus of amino acids. RAG can alternatively or additionally be attached to the side chains of amino acid residues including, but not limited to, aspartic acid and glutamic acid (see Figure 4) to provide additional protection and solubility control when adding these amino acids to the growing sequence.Cleavage of RAG from the side chains of amino acids produces the amide forms of those side chains (here, asparagine and glutamine, respectively) (see FIG. 4).
[0032] In another non-limiting exemplary embodiment, the novel SolPPS method can begin with a novel GAP molecule (here, (Rink Amide)-Phenylalanine-GAP, i.e., RPG) being used for protection of the C-terminus. The RPG can be synthesized similarly to FIG. 5. Specifically, HOBnDpp is attached to Fmoc-protected phenylalanine to form Fmoc-Phenylalanine-GAP (i.e., Fmoc-F-GAP), and after Fmoc deprotection, the now free N-terminus of the GAP-protected phenylalanine is attached to the carboxylic acid moiety of a protected Rink Amide-OH (the molecular structure of the protected Rink Amide-OH can be seen in FIG. 3). The resulting structure can be deprotected at the N-terminus of the Rink Amide molecule, and then the free N-terminus can participate in a coupling reaction to form a peptide bond with the primary amino acid of a given peptide sequence. Peptide synthesis can then proceed in a C to N direction, with the RPG protecting the C-terminus of the growing peptide. RPG as a C-terminal protecting group can be used with any of the disclosed GAP molecules that provide side chain protection, or with other protection strategies available for N-terminus and side chain protection. RPG can also be used to protect the side chain of an amino acid in addition to, or instead of, C-terminal protection, similar to how RAG is used.
[0033] In another non-limiting example, the novel SolPPS method can utilize different novel GAP molecules, such as HG or HPG, for C-terminal protection. The synthesis of these GAP molecules can be seen in FIG. 5, and these molecules can be attached to the C-terminus of peptides to allow for acid-labile C-terminal protection without forming a C-terminal amide upon cleavage (see FIG. 6). Instead of or in addition to protecting the C-terminus of an amino acid, HG and / or HPG can also be attached to the side chains of amino acid residues, including but not limited to aspartic acid, cysteine, serine, threonine, tyrosine, and glutamic acid, to help control solubility (see FIG. 6). Peptide synthesis can then proceed in the C to N direction utilizing a myriad of protection strategies, such as but not limited to the Fmoc / tBu strategy.
[0034] In another non-limiting exemplary embodiment, the novel SolPPS method can begin with the synthesis of aniline diphenylphosphine oxide (i.e., NH2PhDpp), as seen in FIG. 7. Specifically, the synthesis of NH2PhDpp can begin with 4-bromonitrobenzene and can be activated with N-butyl lithium (nBuLi) in an ethereal solvent at ultra-low temperature (-100 to -30°C) and room pressure to form an organolithium reagent. This reagent reacts in situ upon slow addition of chlorodiphenylphosphine to yield NH2PhDpp after phosphine oxidation with hydrogen peroxide and reduction of the nitro group with H2 and 10% Pd / C. This molecule can then be attached, in a non-limiting example, to a Rink Amide-OH (see FIGS. 8, 18), and the resulting GAP molecule can be attached to the C-terminus of a peptide as in FIG. 3 and / or to the side chain of an aspartic acid or glutamic acid (creating a protected asparagine or glutamine, respectively) as in FIG. 4. In another non-limiting example, another novel GAP molecule can be synthesized via reaction of NH2PhDpp with the carboxylic acid moiety of a linker (here, HMPA) directly or via an amine-based intermediate, as seen in Figure 9. The resulting GAP molecule can then be attached to the C-terminus of a peptide and / or to the side chains of aspartic acid, cysteine, serine, threonine, and glutamic acid, as seen in Figure 6. Peptide synthesis can then proceed in the C to N direction utilizing a myriad of protection strategies, including but not limited to the Fmoc / tBu strategy.
[0035] For all of the above non-limiting examples, HOBnDpp, NH2PhDpp, or any other GAP molecule can be attached to the C-terminus or side chain of an amino acid residue in a number of different solvents, including but not limited to dichloromethane, ethyl acetate, isopropyl acetate, methyltetrahydrofuran, tetrahydrofuran, and propylene carbonate. For any of the coupling reactions described herein, whether for the synthesis of the GAP molecule or for the attachment of the GAP molecule to an initial amino acid of the peptide being synthesized, a myriad of different coupling reagents can be used, including but not limited to TFFH, TBTU, HBTU, COMU, or EDCI.
[0036] As a non-limiting exemplary embodiment, and in any of the above examples or combinations thereof, SolPPS can then be accomplished in the C to N direction, such as by using Fmoc / tBu chemistry. Deprotection of the Fmoc groups on the first and subsequent amino acids can be performed with a myriad of deprotection reagents, including diethylamine, DBU (diazabicycloundecene), piperidine, tert-butylamine, and other alkylamines, and additional coupling reactions can be performed to grow the peptide chain. After each coupling reaction, a different quenching agent can be used to neutralize the excess activated amino acids and impart the desired solubility characteristics to the resulting molecule. In a non-limiting example, decylamine can be used to quench the activated amino acids to increase the solubility of the resulting molecule in alkane solvents. Depending on the reaction solvent, liquid-liquid extraction techniques or selective precipitation can then be performed to purify the reaction mixture. The novel GAP molecules disclosed herein allow for the novel SolPPS method to allow for control of solubility and effectively remove amino acid and fulvene impurities (i.e., NFMP) by selective precipitation or extraction. After the last amino acid of the desired peptide sequence is coupled, a global deprotection with an appropriate TFA mixture can be used to remove the acid-labile GAP molecule from the C-terminus and appropriate side chains, in a non-limiting example, and such deprotection can also remove other acid-labile side chain protecting groups, such as tBu-based side chain protecting groups. The novel SolPPS method avoids additional reactions such as hydrogenation or hydrolysis to remove the C-terminus protecting group, and allows for the native peptide sequence to be obtained in one global deprotection step. Furthermore, the use of GAP molecules such as RAG allows for the formation of C-terminal amides upon TFA cleavage, successfully avoiding post-synthetic reactions normally required for such modifications. These novel GAP molecules disclosed herein also remain more stable during peptide synthesis, without accidental hydrolysis or removal due to DKP formation.
[0037] In one non-limiting embodiment, these novel GAP molecules can be used to protect the N-terminus of any given peptide, as well as amine-based side chains of specific amino acid residues, including but not limited to lysine. In a non-limiting example, HPG and diimidazole carbonyl are dissolved in a suitable reaction solvent, such as DCM, and gently stirred at room temperature and pressure for at least 1 hour. An amine is then added to the reaction mixture at room temperature and pressure to yield the HPG-protected carbamate product (see FIG. 17).
[0038] In another non-limiting embodiment, the novel SolPPS method can begin with the synthesis of a novel GAP molecule protecting group, HOBnDpp, NH2PhDpp, or derivatives thereof, can be reacted directly with the carboxylic acid moiety of any given linker molecule, examples of which can be seen in FIG. 18 and the list below. HMPA: 4-(hydroxymethyl)phenoxyacetyl HMPB: 4-(hydroxymethyl)phenoxybutanoyl HMB: 4-(hydroxymethyl)benzoyl MMB: 4-(mercaptomethyl)benzoyl MMPA: 4-(mercaptomethyl)phenoxyacetyl AMPA: 4-(aminomethyl)phenoxyacetyl DMPPA: 4-(3,3-dimethyl-3-hydroxypropyl)phenoxyacetyl Rink Amide: 2-(4-(amino(2,4-dimethoxyphenyl)methyl)phenoxy)acetyl Xanthenyl: 4-((9-amino-9H-xanthen-3-yl)oxy)butanoyl TCA: 5-(5-amino-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-yl)pentanoyl 2-Chlorotrityl: 3-(4-(chloro(2-chlorophenyl)(phenyl)methyl)phenyl)propanoyl
[0039] Examples of such reactions can be seen in Figures 3, 8, 9. These resulting GAP molecules can then be attached to a given amino acid to facilitate C-terminal protection (as in Figure 3), side chain protection (as in Figure 4), or N-terminal protection (similar reactions to those seen in Figure 17). In another non-limiting example, novel GAP molecules can be synthesized by reacting HOBnDpp or a derivative thereof with a given amino acid and then reacting with a given linker molecule at the carboxylic acid moiety as seen in Figures 5 and 9. The resulting GAP molecules can be used for C-terminal protection (as in Figure 3), side chain protection (as in Figure 4), or N-terminal protection (similar to Figure 17).
[0040] The synthetic strategy of the pharmacologically interesting biologically active peptide Bivalirudin is shown as a non-limiting preferred embodiment of the novel method of SolPPS disclosed herein. Figure 6 depicts a schematic for attaching the novel GAP molecule HPG to the C-terminus of an unspecified number of amino acids, which is followed by C-terminal protection with Fmoc-Leucine-OH to form the compound shown in Figure 10. In this particular embodiment, HPG is selected as the C-terminal protecting group to allow post-synthetic deprotection of the acid-labile C-terminus without promoting the formation of a C-terminal amide. This first step is followed by standard Fmoc / tBu chemistry to attach Fmoc-Tyr(tBu)-OH to form an Fmoc-protected dipeptide. The side chain of Fmoc-Glu-OAllyl is then protected with HPG prior to incorporation into the growing peptide, following the amino acid side chain protection schematic shown in Figure 6, to obtain the compound shown in Figure 11. Allyl deprotection of the C-terminus of Fmoc-Glu(HPG)-OAllyl is accomplished by treatment with Pd(PPh3)4 and triisopropyl or phenylsilane, activating the resulting molecule and coupling to the peptide. This process is repeated once more to couple the next HPG-protected glutamic acid residue, resulting in the Fmoc-protected tetrapeptide shown in Figure 12. Standard Fmoc / tBu peptide synthesis is performed, proline and isoleucine are added, and the next two glutamic acid residues are added as described above, followed by phenylalanine. The aspartic acid residue is protected using HPG and added in the same manner as glutamic acid, followed by a glycine residue, according to the schematic shown in Figure 6.
[0041] In another preferred embodiment, the novel GAP molecule RAG is reacted with Fmoc-Asp-OAllyl to yield Fmoc-Asp(RAG)-OAllyl, the compound shown in Figure 13. Allyl deprotection of the compound is then performed, followed by activation and coupling to a peptide chain to yield the Fmoc-protected peptide shown in Figure 14. Standard Fmoc / tBu peptide synthesis is then performed to add four glycines, a proline, an arginine, another proline, and a D-phenylalanine to yield the fully protected bivalirudin peptide, as shown in Figure 15.
[0042] In this particular embodiment, after Fmoc deprotection of the fully protected Bivalirudin, a one-step global deprotection using a TFA mixture (i.e., 90% TFA, 5% HO, 5% triisopropylsilane (TIPS)) can be performed to cleave all side chain protecting groups (including the new GAP molecule), as well as the protecting group at the HPG C-terminus (see FIG. 16). During this global deprotection, the RAG-protected aspartic acid is also converted to deprotected asparagine. The molecule resulting from the global deprotection using a TFA mixture is native Bivalirudin.
[0043] General procedure for Fmoc deprotection and coupling: For the new SolPPS method carried out in propylene carbonate (PC): To amino acids C-terminally protected with Fmoc-(AA)n-OBnDpp, Fmoc-(AA)n-HPG, Fmoc-(AA)n-RAG, or any GAP protecting group pre-dissolved in propylene carbonate (200 mM), a deprotecting agent and octanethiol are added, followed by stirring at room temperature for 15 min in an alkane bilayer. The reaction mixture is then washed twice (x2) with fresh alkane solvent, then three times with saturated aqueous ammonium chloride, and dried. To the separated propylene carbonate solution, 3.0 equivalents (eq) of TBTU or TFFH, 3.0 equivalents of Fmoc-AA-OH, and 3.0 equivalents of diisopropylethylamine (DIPEA) are added and the reaction is stirred for 7 min. This solution is added to the previously dried PC solution containing H-(AA)n- (GAP molecules) and allowed to bind with stirring for 10-60 min. Next, an excess of a quenching agent such as a long-chain (10-18 carbons bonded in a linear chain, i.e., C10-C18) aliphatic thiol, long-chain (C10-C18) aliphatic alcohol, long-chain (C10-C18) aliphatic amine, long-chain (C10-C18) aliphatic selenol, aliphatic polyamine, or aliphatic polyalcohol is added. The reaction mixture is then washed three times with saturated aqueous ammonium chloride and dried to obtain an extended peptide in PC solution. This step is repeated as necessary to generate peptides with the desired sequence and length. For the novel SolPPS method, which is performed in dichloromethane or ethyl acetate: Add a deprotecting agent to an amino acid C-terminally protected with Fmoc-(AA)n-OBnDpp, Fmoc-(AA)n-HPG, Fmoc-(AA)n-RAG, or any GAP protecting group pre-dissolved in DCM or ethyl acetate (100 mM), followed by stirring at room temperature for 10 minutes. The reaction mixture is then washed three times with saturated aqueous ammonium chloride and three times with saturated aqueous sodium bicarbonate, then dried. To the separated DCM or ethyl acetate solution, 2.0 equivalents of TBTU or TFFH, 2.0 equivalents of Fmoc-AA-OH, and 5.0 equivalents of DIPEA are added and the reaction is stirred for 7 minutes. This solution is added to the previously dried DCM or ethyl acetate solution containing H-(AA)n-(GAP molecule) and allowed to combine with stirring for 10-60 minutes.Next, an excess of a quenching agent such as a long-chain (C10-C18) aliphatic thiol, a long-chain (C10-C18) aliphatic alcohol, a long-chain (C10-C18) aliphatic amine, a long-chain (C10-C18) aliphatic selenol, an aliphatic polyamine, or an aliphatic polyalcohol is added. The reaction mixture is then washed three times with saturated aqueous ammonium chloride and dried to obtain the extended peptide in DCM or ethyl acetate solution. This process is repeated as necessary to produce peptides with the desired sequence and length.
[0044] General procedure for EDCI coupling: The reaction mixture containing the deprotected N-terminus of the amino acid or peptide is cooled in an ice bath. Two equivalents of the amino acid to be coupled to such free N-terminus are then added to the reaction mixture, followed by the addition of two equivalents of EDCI. The resulting mixture is removed from the ice bath and stirred for 1 hour, and then an excess of a quenching agent, such as a long-chain (C10-C18) aliphatic thiol, a long-chain (C10-C18) aliphatic alcohol, a long-chain (C10-C18) aliphatic amine, a long-chain (C10-C18) aliphatic selenol, an aliphatic polyamine, or an aliphatic polyalcohol, is added. The reaction mixture is then washed three times with saturated aqueous ammonium chloride and three times with saturated aqueous sodium bicarbonate, and then dried.
[0045] In another embodiment, the disclosure can include a chemical composition including a group assisted purification (GAP) component and a linker component. In one embodiment, the GAP component can be any molecule that exhibits the properties of a GAP molecule or anchor described herein, such as a GAP molecule that is capable of precipitation from a non-polar organic solvent. For example, the GAP component can be sufficiently polar such that it is not soluble in a non-polar organic solvent, such as petroleum ether, hexane, heptane, etc. In another example, the GAP component can include a polar bond sufficient to render the GAP component insoluble in a non-polar organic solvent, such as a phosphate-oxygen bond (phosphine oxide), a sulfur-oxygen bond, a nitrogen-oxygen bond, or other polar bond sufficient to render the GAP component insoluble in a non-polar organic solvent. In another embodiment, the GAP component can include a moiety that imparts π-π stacking, such as an aromatic moiety, for example, the GAP component can include one or more phenyl substituents. In another embodiment, the GAP component can be any molecule suitable for excluding itself from a non-polar organic solvent. In another embodiment, the GAP component can include a nucleophilic moiety that can participate in a coupling reaction. For example, the GAP component can include an alcohol, an amine, a thiol, or other nucleophilic moiety. In another embodiment, the GAP component can impart its solubility properties to the molecule to which it is attached. In another embodiment, the GAP component can include a hydrocarbon moiety, preferably the hydrocarbon moiety can include at least 6 carbon atoms. In another embodiment, the GAP component can include an alkyl moiety, preferably the alkyl moiety can include 6 to 30 carbons.
[0046] Preferably, the GAP component comprises a polar covalent bond with a significant charge distribution. In one embodiment, the significant charge distribution may result from a mismatch in the size of the p orbitals of the binding atoms, and in another embodiment, the significant charge distribution may result from all of the p orbitals of one of the binding atoms being hybridized resulting in reduced π overlap, which may cause charge separation. In another embodiment, the GAP component may further comprise one or more aromatic moieties to allow π-π stacking, which may facilitate crystallization upon precipitation and also reduce water solubility. In another embodiment, the GAP component may further comprise additional alkyl substituents which may further reduce aqueous solubility. In another embodiment, the GAP component may comprise a nucleophilic moiety capable of participating in a nucleophilic substitution reaction, such as a coupling reaction, which is known in the art, particularly for peptide synthesis. In one embodiment, the GAP component may comprise a free alcohol, an amine, or other nucleophilic moiety capable of participating in a nucleophilic substitution reaction. In another embodiment, the GAP component is preferably between 250 and 1250 Daltons.
[0047] For example, in one embodiment as shown in FIG. [ka] teeth, [ka] may include.
[0048] In the formula, A 1 are S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH2) j - (wherein "j" is as defined below); A 2 are S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH2) k - (wherein "k" is as defined below); A 3is selected from the group consisting of S, O, NH, NMe, NEt, NBn, and NPh; R 4 is -(CH2) m -H (wherein "m" is as defined below), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 5 is -(CH2) p -Me (wherein "p" is as defined below), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 6 = Dpp; Dpop; or Dap, in which [ka] is [ka] is an abbreviation for [ka] is [ka] is an abbreviation for [ka] is [ka] is an abbreviation for ;R 7 is C y H (2y+1) (wherein "y" is as defined below), OC y H (2y+1) (wherein "y" is as defined below), NHC y H (2y+1)(wherein "y" is as defined below), (2-ethyl)hexyl, and isooctyl; and j, k, m, p, and y are separate numbers selected from the group consisting of any integer between 0 and 30.
[0049] The moieties discussed herein can be attached to other moieties or molecules, as indicated by the wavy lines above.
[0050] In one embodiment, the linker component can include any of the linker molecules discussed herein. For example, the linker component can take substantially the form of any of the linker molecules depicted in FIG. 18 and discussed herein. In another embodiment, the linker component can include a molecule having a first and a second chemical moiety. In one embodiment, the first moiety can be capable of forming a bond with the GAP moiety or the spacer moiety (discussed further below). For example, the first moiety can include an electrophile capable of participating in a nucleophilic substitution reaction, such as a coupling reaction. In another example, the first moiety can be a carbonyl, and in another example, the first moiety can be a carboxylic acid moiety. In another embodiment, the second moiety can be capable of forming a bond with an amino acid. For example, the second moiety can be a free alcohol, an amine, or other nucleophilic moiety. In another example, the second moiety can be capable of participating in a coupling reaction. In another example, the second moiety can be capable of forming a bond with the C-terminus of an amino acid. In one embodiment, the linker moiety can be a molecule capable of linking the GAP moiety to another molecule, and in another embodiment, the linker moiety can be a molecule capable of linking the spacer moiety to which the GAP moiety is attached to the target molecule. In another embodiment, the linker moiety can be configured such that if a charge arises on the atom adjacent to the nucleophilic moiety, that charge can be stabilized through resonance or conjugation. For example, with respect to the RAG molecules discussed herein, the linker moiety (in this example, Rink Amide) can generate a charge on the benzyhydryl carbon upon cleavage of the carbon-nitrogen bond that leaves the nitrogen attached to the target molecule. The linker moiety (and thus the GAP anchor containing the linker moiety) can include a conjugation that can stabilize the charge that arises on the benzydryl carbon such that the cleavage reaction to remove the GAP anchor from the target molecule is energetically favorable. In another embodiment, the charge that arises on the carbon adjacent to the nucleophilic moiety can be stabilized by the fact that the carbon atom is a trisubstituted (tertiary) carbon.In another embodiment, the linker moiety can be attached to the targeting molecule via a bond that is susceptible to cleavage under hydrolysis conditions known in the art.
[0051] Preferably, the linker moiety can allow a composition comprising the linker moiety and the GAP moiety to be removably attached to another molecule via the second portion of the linker moiety. For example, the first portion of the linker moiety can participate in a bond with either the GAP moiety or the spacer moiety, and such bond can be stable to a myriad of conditions, such as acid and base deprotection reactions known in the art (i.e., global deprotection with TFA, hydrolysis reactions, etc., as discussed herein). In this way, the composition can be resistant to degradation and maintain its chemical structure under many conditions. Preferably, the bond formed between the second portion of the linker moiety and another molecule can be labile to reactions in which the bond of the first moiety is stable. In this way, the composition can be cleaved from another molecule at the second portion of the linker moiety while maintaining the bond between the first moiety and either the spacer moiety or the GAP moiety. In one embodiment, this functionality (i.e., orthogonality of the bond of the second moiety to the bond of the first moiety) can be enabled by the unique structure of the linker moiety, such as those described in Figures 19 and 22A. For example, a linker moiety can be specifically designed to exhibit this functionality, such as using linker molecules known in the art, examples of which can be found in Figures 19 and 22A. In another embodiment, the bond between the first moiety and either the spacer moiety or the GAP moiety, and the bond between the second moiety and another molecule can be cleavable under the same conditions.
[0052] For example, the linker component may be exemplified by HMPA-OH as seen in FIG. 5. HMPA-OH comprises a first and a second chemical moiety. The first moiety of HMPA-OH is a carboxylic acid that is vulnerable to nucleophilic attack - thus, a nucleophilic moiety (e.g., a nucleophile of a GAP component, or the N-terminus of an amino acid) can form a bond with the first moiety of HMPA-OH via nucleophilic displacement. The second moiety of HMPA-OH is a benzyl alcohol, which itself is a nucleophilic moiety that can attack an electrophile, such as the carbonyl carbon of the C-terminus of an amino acid, to form a bond by nucleophilic displacement as well. Furthermore, the structure of HMPA-OH allows the bond formed with the second moiety of the linker component to be cleaved under strong acid conditions. Preferably, the bond formed with the first moiety (such as a bond with HOBnDpp, or an amino acid, as depicted in FIG. 5) remains stable to such conditions.
[0053] In one embodiment, a linker moiety that can be attached to two other moieties (i.e., a GAP moiety, another linker moiety, a spacer moiety, or any combination thereof) [ka] As can be seen in FIG. 20A, [ka] may include.
[0054] wherein X is selected from the group consisting of Y (defined below), -C(O)-, and -(CH2) a - (wherein "a" is as defined below); Y is selected from the group consisting of S, NH, NMe, NEt, NBn, NPh, and O; R 1 is -(CH2) b -H (wherein "b" is as defined below), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 2 is -(CH2)c is selected from the group consisting of -H (wherein "c" is as defined below), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; and a, b, c, and n are separate numbers selected from the group consisting of any integer between 0 and 30.
[0055] In one embodiment, a linker moiety that can be attached to three other moieties (i.e., a GAP moiety, another linker moiety, a spacer moiety, or any combination thereof) [ka] As can be seen in FIG. 20A, [ka] may include.
[0056] wherein X is selected from the group consisting of Y (defined below), -C(O)-, and -(CH2) a - (wherein "a" is as defined below); Y is selected from the group consisting of S, NH, NMe, NEt, NBn, NPh, and O; R 1 is -(CH2) b -H (wherein "b" is as defined below), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 2 is -(CH2) c is selected from the group consisting of -H (wherein "c" is as defined below), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; and a, b, c, and n are separate numbers selected from the group consisting of any integer between 0 and 30.
[0057] In another embodiment, the present disclosure can include a chemical composition comprising a GAP component, a linker component (linker), and a spacer component (spacer). In one embodiment, the spacer can be any molecule capable of facilitating a connection between the GAP component and the linker component. For example, the spacer component can include a first moiety operable to bind to the GAP component and a second moiety operable to bind to the linker component. In one embodiment, the spacer can be an amino acid having a C-terminus and an N-terminus, where the C-terminus can bind to a nucleophilic moiety of the GAP component and the N-terminus can bind to an electrophilic moiety of the linker. In another embodiment, the spacer can impart a desired solubility characteristic to the overall chemical composition. For example, the spacer can include an alkyl chain, an amino acid, a polar organic moiety, or any other chemical moiety that exhibits a desired solubility characteristic. In another embodiment, the spacer component can provide sufficient non-conjugated physical separation between the linker component and the GAP component, such as through a series of sp3 hybridized carbon atoms, such that the GAP component and the linker component are electronically separated from each other. Such separation can prevent either component from negatively affecting the other, which may interfere with the properties exhibited by each component disclosed herein. For example, the spacer component can prevent the chemical-electronic properties of the GAP component from interfering with the conjugation found in the linker component, such as a conjugation that allows the bond formed by the second portion of the linker to be cleavable under known conditions. In another example, a spacer can be placed between the GAP portion and the linker component that can participate in coupling or other bond-forming reactions with each other, thereby providing a distance between them that reduces steric hindrance that may make the reaction inefficient.
[0058] In one embodiment, a linker moiety that can be attached to two other moieties (i.e., a GAP moiety, a linker moiety, another spacer moiety, or any combination thereof) [ka] As can be seen in FIG. 20B, [ka] may include.
[0059] In the formula, Z 1 are S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH2) d - (wherein "d" is as defined below); Z 2 are S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH2) e - (wherein "e" is as defined below); R 3 is H, methyl, ethyl, propyl, isopropyl, benzyl, isobutyl, sec-butyl, tert-butyl, 2-(methylmercapto)ethyl, and the structure shown below. [ka] is selected from the group consisting of:
[0060] In the formula, d, e, f, g, h, and i are individual numbers selected from the group consisting of integers between 0 and 30.
[0061] In one embodiment, the present disclosure can include a group-assisted purification (GAP) anchor molecule. For example, the GAP anchor (anchor molecule) (GAP molecule) (GAP protecting group) can be the product of the reaction shown in FIG. 19. In another example, the GAP anchor can be RAG, HPG, or NH2PhDpp, as described herein and shown in FIG. 3, FIG. 5, and FIG. 7, respectively. In another embodiment, the GAP anchor can be a molecule defined in FIG. 20A-F, FIG. 21A-B, and FIG. 22. In another example, the GAP anchor can be a GAP moiety. In another embodiment, the GAP anchor can be a molecule comprising a GAP moiety and a linker moiety, and in another embodiment, the GAP anchor can include a GAP moiety, a linker moiety, and a spacer moiety. For example, the GAP anchor can incorporate any number of GAP moieties, linker moieties, or spacer moieties. Preferably, the GAP anchor (H-Anchor) can take the form shown in FIG. 20A. H-Gap, H-Linker-Gap, [ka] , H-Linker-Spacer-Gap or [ka] These types of structures are collectively known as H-Anchor molecules, where H is the element hydrogen, and the Linker, Spacer, and Gap molecules are as defined below.
[0062] Preferably, different combinations of GAP, linker, and spacer components can be used to achieve specific objectives, as illustrated in Figures 20A-20C. For example, the HPG molecule can be an example of a GAP anchor (H-Anchor) discussed herein. As seen in Figure 5, the linker component can be, for example, HMPA-OH, which can be attached to a GAP component (e.g., OBnDpp) via a spacer component (e.g., phenylalanine) to form an exemplary GAP anchor, HPG. The linker component can include HMPA-OH, which has an electrophilic moiety (i.e., carbonyl) that can participate in a nucleophilic substitution reaction, and a nucleophilic moiety. When the nucleophile of the GAP component (i.e., HOBnDpp) attacks the carbonyl, a bond can be formed via nucleophilic substitution. The nucleophilic moiety (i.e., benzyl alcohol) of HMPA-OH can then act as a nucleophile itself and attack an electrophilic moiety, such as the C-terminus of an amino acid. Alternatively, a GAP moiety linked to a spacer (eg, phenylalanine) can be linked to HMPA-OH to form the GAP anchor HPG.
[0063] For example, as shown in FIG. 20D, the GAP anchor (H-Anchor) is [ka] may include.
[0064] In this embodiment, H-Anchor (GAP anchor) has the following specific components: [ka] The H-Linker-Spacer-GAP format has the following structure:
[0065] In the formula, Y=O;R 1 =H;R 2 =H;X=parallel O;Z 1 =-(CH2)-, d=1; f=8; R 3 =H;g=0;Z 2=-C(O)-;A 1 =NH;A 2 = O in the para position; and R 6 =Dpp.
[0066] In another embodiment, as shown in FIG. 20E, the H-Anchor is [ka] may include.
[0067] In this embodiment, the GAP anchor is [ka] It is an H-Gap format having the following structure:
[0068] In the formula, A 1 =O;R 4 =H;R 5 =-(CH2) p -Me, where p=0;A 2 = Para position -(CH2) k where k=0; and R 6 =Dpp.
[0069] In another example, the GAP anchor is [ka] may include.
[0070] This H-Anchor molecule has the following specific components: [ka] The H-Linker-Spacer-Gap format includes the following:
[0071] In the formula, Y=O;R 1 =H;R 2 =H; X=para O; n=1; Z 1 =NH;f=0;R 3is as defined above, h=2; g=0; Z 2 =-C(O)-;A 1 =O;R 4 =H;R 5 =-(CH2) p -Me, where p=0;A 2 = Para position -(CH2) k - where k=0; R 6 = Dpp; and R 3 = [ka] It is.
[0072] In another embodiment, the present disclosure provides a method for manufacturing a semiconductor device, as shown in FIG. [ka] and the like.
[0073] wherein Y is selected from the group consisting of S, O, NH, NMe, NEt, and N-iPr; 1 is H, -(CH2) a -H (wherein "a" is selected from the group consisting of any integer from 0 to 30), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 2 is -(CH2) b -H (wherein "b" is an integer from 1 to 30), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 6 is C y H (2y+1) (wherein "y" is an integer from 1 to 30), YC y H (2y+1) (wherein "y" is an integer from 1 to 30, and Y is as defined above), (2-ethyl)hexyl, and isooctyl; L is hydrogen or [ka] Either:
[0074] In the formula, Z is selected from the group consisting of S, O, NH, NMe, NEt, and N-iPr; X is selected from the group consisting of S, O, NH, NMe, NEt, and N-iPr; n is selected from the group consisting of any integer from 0 to 30; R 3 is H, -(CH2) c -H (wherein "c" is selected from the group consisting of any integer from 0 to 30), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 4 is H, -(CH2) d -H (wherein "d" is selected from the group consisting of any integer from 0 to 30), -CCl3, -CF3, phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; [ka] is the point of attachment to other components; R 5 teeth, [ka] It can be.
[0075] During the ceremony, [ka] is the point of attachment to L; e is selected from the group consisting of any integer from 0 to 30; e, f, and g are selected from the group consisting of any integer from 0 to 30.
[0076] In another embodiment, the present disclosure provides the [ka] and the like (such as the anchor molecules disclosed herein).
[0077] In one embodiment, the GAP, linker, and spacer moieties can be considered as three separate chemical entities that can confer different useful properties to a given GAP anchor. For example, the GAP moiety can be a GAP molecule that includes a polar bond (e.g., a phosphine oxide) and an aromatic moiety, which ultimately gives the GAP anchor a polar organic character with the potential for π-π stacking that can help the GAP anchor (and the attached target molecule) to selectively precipitate from non-polar solvents, which in another embodiment can aid the GAP anchor in excluding itself from aqueous and non-polar solvents. In one embodiment, in the same GAP anchor, a linker moiety, as seen in Figures 19 and 22A, can confer the anchor the ability to be selectively removed from a desired substrate, as with the RAG and HPG anchors discussed herein, which can be removed, for example, from the C-terminus or N-terminus or side chain of an amino acid or peptide. For example, the linker moiety can be specifically designed to form a non-labile bond in one location and a labile bond in yet another location. This orthogonality is ultimately reflected in the GAP anchor, where the GAP moiety and the linker moiety together thus confer a polar organic nature to the GAP anchor suitable for group-assisted purification chemistry, and the GAP anchor can be further cleaved under conditions suitable for the linker moiety itself. In another embodiment, in the same GAP anchor, the spacer moiety can impart further desirable properties to the GAP anchor. For example, the spacer can be highly organic or non-polar, increasing the overall solubility of the GAP anchor in non-polar solvents, and in another example, the spacer can be highly polar, making the GAP anchor more polar and therefore less soluble in non-polar organic solvents.
[0078] In accordance with the principles of the present disclosure, the GAP anchor can be specially formulated to thereby aid in the synthesis of a given molecule with specific properties. For example, as further discussed herein, a desired peptide can be synthesized with the aid of a GAP anchor. The GAP moiety of the anchor can have properties discussed herein that aid in solubilizing the anchor (and the attached peptide) in organic solvents, and the GAP moiety may also be suitable for π-π stacking to aid the peptide in selective precipitation, such as via dropwise precipitation. A spacer moiety can be attached to the GAP moiety, which can be, for example, an amino acid, to further control solubility by providing multiple attachment points for different aforementioned moieties, and additional sites as needed to achieve desired properties. And a linker moiety can be used to attach to the spacer to form a stable product, and can further have a free moiety that can participate in a reaction, such as a coupling reaction. Preferably, the bond formed by the free moiety of the linker moiety can be labile to TFA deprotection known in the art, such as those discussed herein.
[0079] Different GAP components can offer different advantages, for example, more polar or charged substituents can increase solubility in polar solvents and decrease solubility in non-polar solvents; more polar bonds can increase solubility in polar organic solvents; more organic or aliphatic substituents can increase solubility in organic solvents while decreasing solubility in aqueous solvents; more π bonds and aromatic substituents are better for precipitation by π-π stacking, and larger GAP components can exhibit dissolution control effects on larger target molecules. Similarly, different spacer moieties can provide different advantages, for example, a smaller spacer can have less of an overall effect on the solubility properties of the GAP anchor, yet still provide assistance in attaching the GAP moiety to the linker moiety to form a stable compound; a more polar spacer can increase the solubility of the anchor in polar solvents; a more organic or aliphatic spacer can increase the solubility in organic solvents; a longer spacer can reduce the possibility of steric hindrance at the attachment point of a given GAP moiety to the linker moiety; a smaller spacer can allow for a higher overall product loading of the target substrate and GAP anchor by reducing the molecular weight of the GAP anchor compared to a larger spacer. Similarly, different linker moieties can provide different advantages, for example, different cleavage conditions from the target substrate (i.e., acid catalysis, base catalysis, etc.), for example, C-terminal modifications upon cleavage of the GAP anchor from a peptide (such as the RAG molecules discussed herein). Different linkers can also provide different degrees of stability during peptide synthesis, for example, a linker may be more or less resistant to premature hydrolysis or diketopiperazine (DKP) formation. Also, depending on the site of a given linker, different linkers can enhance solubility in different solvents, with more organic linkers enhancing the solubility of the anchor in organic solvents and more polar linkers enhancing solubility in polar or polar organic solvents. Those skilled in the art will appreciate that the GAP anchor can take advantage of these different components to provide an anchor specialized for a given chemical synthesis strategy.
[0080] In another embodiment, the disclosure can include a method for synthesizing a peptide, the method can include binding a first amino acid to an anchor molecule, the anchor molecule including a group assisted purification (GAP) component and a linker component, the first amino acid being bound to the linker component of the anchor molecule, forming a peptide bond between a second amino acid and the first amino acid, and removing the anchor molecule from the first amino acid. The method can further include an anchor including a spacer component disposed between the GAP component and the linker component. In one embodiment, the spacer component can be an amino acid. In another embodiment, the disclosure can include a method for synthesizing a peptide using the GAP molecules disclosed herein, such as those in FIG. 21A, FIG. 21B, and FIG. 22. In one embodiment, the peptide synthesis method can allow for improved solubility control over the target peptide by using anchor molecules that affect the properties of each component. Anchor molecules as discussed herein can be attached to the C-terminus, N-terminus, or side chain of a given amino acid for incorporation into the peptide. Those skilled in the art will appreciate that such methods may be used to synthesize peptides of any desired length containing any desired number of amino acids.
[0081] In another embodiment, the present disclosure provides a method for, for example, the method of FIG. [ka] The present invention can include a method for synthesizing a GAP anchor, such as:
[0082] In another embodiment, a method for synthesizing an H-Anchor molecule (anchor molecule) can be, for example, as shown in FIG. 23B: [ka] may include.
[0083] In one embodiment, each component (i.e., GAP, spacer, and linker components) can be considered as reactants in a given synthesis strategy. For example, in FIG. 23A, compound 3 can be considered as the GAP component, i.e., group-assisted purification molecule. Compound 4 can be considered as a spacer component that, when coupled to the GAP component, can facilitate coupling to a linker component, such as compound 6. The final resulting GAP anchor, compound 7, can then be reduced with a free linker moiety to provide a benzyl alcohol that can participate in nucleophilic substitution reactions, such as coupling reactions known in the art for peptide chemistry. In another example, such as in FIG. 23B, the GAP component can take the form of either ClPPh2 or compound 2. The spacer component can be oleylamine, which, when coupled to the GAP component, can form a GAP-spacer molecule, such as compound 3. This can then be coupled to a linker component, such as compound 4, to ultimately obtain a GAP anchor, such as compound 5.
[0084] Additional embodiments of the claimed invention include the following.
[0085] 1. A protecting group for solution phase peptide synthesis, the protecting group having a formula selected from the group consisting of: 1, 2, 3, 4, 5, 6, 7, and 8; In the formula, Chemical Formula 1 is [ka] and chemical formula 2 is [ka] and formula 3 is [ka] and formula 4 is [ka] and formula 5 is [ka] and formula 6 is [ka] and formula 7 is [ka] and formula 8 is [ka] where: Z is selected from the group consisting of -H, a methyl group (-Me), and a methoxy group (-OMe); Y is selected from the group consisting of -O-, -S-, and -NH-; X is selected from the group consisting of -O-, -S-, and -NH-; R is selected from the group consisting of the known side chains of protected amino acids and the known side chains of unprotected amino acids; L is an abbreviation for 4-(hydroxymethyl)phenoxyacetyl ("HMPA"), 4-(hydroxymethyl)phenoxybutanoyl ("HMPB"), 4-(hydroxymethyl)benzoyl ("HMB"), 4-(mercaptomethyl)benzoyl ("MMB"), 4-(mercaptomethyl)phenoxyacetyl ("MMPA"), 4-(aminomethyl)phenoxyacetyl ("AMPA"), 4-(3,3-dimethyl-3-hydroxypropyl)phenoxyacetyl ("DMPPA"), 2-(4-(amino(2,4-dimethoxyphenyl)methyl)phenoxy)acetyl ("Rink Amide"), 4-((9-amino-9H-xanthen-3-yl)oxy)butanoyl ("xanthenyl"), 5-(5-amino-10,11-dihydro-5H-dibenzo[a,d][7]annulen-3-yl)pentanoyl ("TCA"), and 3-(4-(chloro(2-chlorophenyl)(phenyl)methyl)phenyl)propanoyl ("2-chlorotrityl"); Protecting group.
[0086] 2. The protecting group according to paragraph 1, wherein the protecting group is selected from the group consisting of formula 1, formula 4, formula 5, and formula 7, and R is a side chain of an amino acid.
[0087] 3. The protecting group according to clause 1, wherein R is selected from the group consisting of -H, methyl, -CH2SH, -CH2CH2COOH, -CH2COOH, benzyl, 4-(1H-imidazolyl)methyl, -CH(CH3)(CH2CH3), -CH2CH2CH2NH2, -CH2CH2CH2NH2, isobutyl, -CH2CH2SCH3, -CH2CONH2, -CH2CH2CONH2, a propyl group with the 1-position of the propyl group bonded to the same position as the R group and the 3-position of the propyl group bonded to the nitrogen, -CH2CH2CH2N=C(NH2)2, -CH2OH, 1-hydroxyethyl, isopropyl, 4-hydroxybenzyl, and 3-(1H-indolyl)methyl.
[0088] 4. A method for performing solution phase peptide synthesis, the method comprising: attaching a first protecting group to a first amino acid to provide a first protected amino acid, the first protecting group being a protecting group of claim 1; performing a coupling reaction on the first protected amino acid or on a peptide formed by coupling the first amino acid to another molecule; A method comprising:
[0089] 5. The method of clause 4, wherein the first protecting group is attached to the C-terminus of the first amino acid.
[0090] 6. The method of clause 4, wherein a first protecting group is attached to the side chain of a first amino acid.
[0091] 7. The method of claim 4, wherein the first protecting group is attached to the N-terminus of the first amino acid.
[0092] 8. The method, coupling a second protected amino acid to the first protected amino acid; Including, the second protected amino acid comprises a second protecting group and a second amino acid, the second amino acid comprises a side chain, the second protecting group is attached to the side chain of the second amino acid, and the second protecting group has a formula selected from the group consisting of: The method according to clause 4.
[0093] 9. The method of claim 8, wherein the step of attaching a first protecting group comprises attaching the first protecting group to the C-terminus of the first amino acid, the N-terminus of the first amino acid, or a side chain of the first amino acid.
[0094] 10. A method for forming a protecting group for solution phase peptide synthesis, the method comprising: Attaching benzyldiphenylphosphine oxide (HOBnDpp), anilinediphenylphosphine oxide (NH2PhDpp), or a derivative thereof to the linker molecule (i) directly, (ii) via an amino acid, or (iii) via an amino acid derivative; A method comprising:
[0095] 11. The bonding step comprises: [ka] to L-OH to form a protecting group, the protecting group being represented by formula I [ka] wherein: R is selected from the group consisting of the known side chains of protected and unprotected amino acids; L is selected from the group consisting of HMPA, HMPB, HMB, MMB, MMPA, AMPA, DMPPA, Rink Amide, xanthenyl, TCA, and 2-chlorotrityl; 11. The method according to claim 10.
[0096] 12. The bonding step comprises: [ka] to L-OH to form a protecting group, the protecting group being represented by formula 2 [ka] wherein: L is selected from the group consisting of HMPA, HMPB, HMB, MMB, MMPA, AMPA, DMPPA, Rink Amide, xanthenyl, TCA, and 2-chlorotrityl; 11. The method according to claim 10.
[0097] 13. The bonding step comprises: [ka] to L-OH to form a protecting group, the protecting group being represented by formula 3 [ka] wherein: L is selected from the group consisting of HMPA, HMPB, HMB, MMB, MMPA, AMPA, DMPPA, Rink Amide, xanthenyl, TCA, and 2-chlorotrityl; 11. The method according to claim 10.
[0098] 14. The bonding step comprises: [ka] to L-OH to form a protecting group, the protecting group being represented by formula 4 [ka] wherein: R is selected from the group consisting of the known side chains of protected and unprotected amino acids; L is selected from the group consisting of HMPA, HMPB, HMB, MMB, MMPA, AMPA, DMPPA, Rink Amide, xanthenyl, TCA, and 2-chlorotrityl; 11. The method according to claim 10.
[0099] 15. The bonding step comprises: [ka] to L-OH to form a protecting group, the protecting group being represented by formula 5 [ka] wherein: Z is selected from the group consisting of -H, -Me, and -OMe; Y is selected from the group consisting of -O-, -S-, and -NH-; R is selected from the group consisting of the known side chains of protected and unprotected amino acids; L is selected from the group consisting of HMPA, HMPB, HMB, MMB, MMPA, AMPA, DMPPA, Rink Amide, xanthenyl, TCA, and 2-chlorotrityl; 11. The method according to claim 10.
[0100] 16. The bonding process comprises: [ka] to L-OH to form a protecting group, the protecting group being represented by formula 6 [ka] wherein: Z is selected from the group consisting of -H, -Me, and -OMe; Y is selected from the group consisting of -O-, -S-, and -NH-; L is selected from the group consisting of HMPA, HMPB, HMB, MMB, MMPA, AMPA, DMPPA, Rink Amide, xanthenyl, TCA, and 2-chlorotrityl; 11. The method according to clause 10.
[0101] 17. The bonding process comprises: [ka] to L-OH to form a protecting group, the protecting group being represented by formula 7 [ka] wherein: Z is selected from the group consisting of -H, -Me, and -OMe; Y is selected from the group consisting of -O-, -S-, and -NH-; X is selected from the group consisting of -O-, -S-, and -NH-; R is selected from the group consisting of the known side chains of protected and unprotected amino acids; L is selected from the group consisting of HMPA, HMPB, HMB, MMB, MMPA, AMPA, DMPPA, Rink Amide, xanthenyl, TCA, and 2-chlorotrityl; 11. The method according to clause 10.
[0102] 18. The bonding process comprises: [ka] to L-OH to form a protecting group, the protecting group being represented by formula 8 [ka] wherein: Z is selected from the group consisting of -H, -Me, and -OMe; Y is selected from the group consisting of -O-, -S-, and -NH-; X is selected from the group consisting of -O-, -S-, and -NH-; R is selected from the group consisting of the known side chains of protected and unprotected amino acids; L is selected from the group consisting of HMPA, HMPB, HMB, MMB, MMPA, AMPA, DMPPA, Rink Amide, xanthenyl, TCA, and 2-chlorotrityl; 11. The method according to claim 10.
Claims
1. A chemical composition comprising a GAP moiety, a spacer moiety, and a linker moiety, wherein the spacer moiety is disposed between the GAP moiety and the linker moiety; The GAP component is Formula A 【Chemistry 1】 , formula B 【Chemistry 2】 , formula C 【Chemistry 3】 , formula D 【Chemistry 4】 , formula E 【Chemistry 5】 and formula F 【Chemistry 6】 wherein: A 1 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH 2 ) j -, where "j" is as defined below; A 2 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH 2 ) k -, where "k" is as defined below; A 3 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, and NPh; R 4 is selected from the group consisting of -(CH 2 ) m -H (where "m" is defined below), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 5 is selected from the group consisting of -(CH 2 ) p -Me (where "p" is defined below), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 6 is selected from the group consisting of Dpp, Dpop, and Dap, 【Chemistry 7】 But the following 【Chemistry 8】 is an abbreviation for 【Chemistry 9】 But the following 【Chemistry 10】 is an abbreviation for 【Chemistry 11】 But the following 【Chemistry 12】 is an abbreviation for; R 7 is selected from the group consisting of C y H (2y+1) (wherein "y" is defined below), OC y H (2y+1) (wherein "y" is defined below), NHC y H (2y+1) (wherein "y" is defined below), (2-ethyl)hexyl, and isooctyl; j, k, m, p, and y are separate numbers selected from the group consisting of any integer between 0 and 30; The linker moiety is Formula I 【Chemistry 13】 , formula II 【Chemistry 14】 , formula III 【Chemistry 15】 , formula IV 【Chemistry 16】 , formula V 【Chemistry 17】 , Formula VI 【Chemistry 18】 and Formula VII 【Chemistry 19】 wherein: X is selected from the group consisting of Y (defined below), -C(O)-, and -(CH2)a-, where "a" is defined below; Y is selected from the group consisting of S, NH, NMe, NEt, NBn, NPh, and O; R 1 is selected from the group consisting of -(CH 2 ) b -H (where "b" is defined below), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 2 is selected from the group consisting of -(CH 2 ) c -H (where "c" is defined below), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; a, b, c, and n are separate numbers selected from the group consisting of any integer between 0 and 30; or The linker component may be 4-(hydroxymethyl)phenoxyacetyl ("HMPA"), 4-(hydroxymethyl)phenoxybutanoyl ("HMPB"), 4-(hydroxymethyl)benzoyl ("HMB"), 4-(mercaptomethyl)benzoyl ("MMB"), 4-(mercaptomethyl)phenoxyacetyl ("MMPA"), 4-(aminomethyl)phenoxyacetyl ("AMPA"), 4-(3,3-dimethyl-3-hydroxypropyl)phenoxyacetyl ("DMPPA"), 2-(4-(amino(2,4-dimethoxyphenyl)methyl)phenoxy)acetyl ("Rink Amide"), 4-((9-amino-9H-xanthen-3-yl)oxy)butanoyl ("xanthenyl"), 5-(5-amino-10,11-dihydro-5H-dibenzo[a,d][7]annulen-3-yl)pentanoyl ("TCA"), and 3-(4-(chloro(2-chlorophenyl)(phenyl)methyl)phenyl)propanoyl ("2-chlorotrityl"); The spacer moiety is Formula X 【Chemistry 20】 and formula Y 【Chemistry 21】 wherein: Z 1 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH 2 ) d -, where "d" is as defined below; Z 2 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH 2 ) e -, where "e" is as defined below; d, e, f, g, h, i, and z are separate numbers selected from the group consisting of any integer between 0 and 30; R 3 is H, methyl, ethyl, propyl, isopropyl, benzyl, isobutyl, sec-butyl, tert-butyl, 2-(methylmercapto)ethyl, and the structures shown below: Formula 1 【Chemical 22】 , Equation 2 【Chemistry 23】 , Equation 3 【Chemistry 24】 , Equation 4 【Chemistry 25】 , Equation 5 【Chemistry 26】 , Equation 6 【Chemistry 27】 , Equation 7 【Chemistry 28】 , Equation 8 【Chemical 29】 , Equation 9 【Chemistry 30】 , Equation 10 【Chemistry 31】 , Equation 11 【Chemistry 32】 , Equation 12 【Chemical 33】 , Equation 13 【Chemical 34】 , Equation 14 【Chemistry 35】 , Equation 15 【Chemical 36】 , Equation 16 【Chemical 37】 , Equation 17 【Chemical Formula 38】 , and Equation 18 【Chemical Formula 39】 A chemical composition selected from the group consisting of:
2. The GAP component is Formula B 【Chemistry 40】 and the linker moiety is Formula I 【Chemistry 41】 and the spacer moiety is Formula X 【Chemistry 42】 2. The composition of claim 1 , 【Request 3】 【Chemical 43】 The composition of claim 2 comprising:
4. The GAP component is Formula A 【Chemistry 44】 and the linker moiety is Formula III 【Chemistry 45】 and the spacer moiety is Formula X 【Chemistry 46】 2. The composition of claim 1 ,
5. 【Chemical 47】 The composition of claim 4 comprising:
6. Formula A 【Chemistry 48】 , formula B 【Chemistry 49】 , formula C 【Chemistry 50】 , formula D 【Chemistry 51】 , formula E 【Chemistry 52】 , formula F 【Chemistry 53】 , formula G 【Chemical 54】 , formula H 【Chemistry 55】 , Formula I 【Chemistry 56】 and formula J 【Chemistry 57】 A chemical composition comprising a GAP anchor selected from the group consisting of: Y is selected from the group consisting of S, O, NH, NMe, NEt, and NiPr; R 1 H, -(CH 2 ) a -H (wherein "a" is selected from the group consisting of any integer from 0 to 30), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 2 But -(CH 2 ) b -H (wherein "b" is an integer from 1 to 30), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 6 But, C y H (2y+1) (wherein "y" is an integer from 1 to 30), YC y H (2y+1) wherein "y" is an integer from 1 to 30, and Y is as defined above, selected from the group consisting of (2-ethyl)hexyl, and isooctyl; For formula A, formula B, formula C, formula D, and formula E, L is H, Formula 1 【Chemistry 58】 , Equation 2 【Chemistry 59】 , Equation 3 【Chemistry 60】 , Equation 4 【Chemistry 61】 , Equation 5 【Chemistry 62】 , Equation 6 【Chemistry 63】 , Equation 7 【Chemistry 64】 , Equation 8 【Chemistry 65】 , and Equation 9 【Chemistry 66】 is selected from the group consisting of For Formula F, Formula G, Formula H, Formula I, and Formula J, L is selected from the group consisting of Formula 1, Formula 2, Formula 3, Formula 4, Formula 5, Formula 6, Formula 7, Formula 8, and Formula 9, Z is selected from the group consisting of S, O, NH, NMe, NEt, and NiPr; X is selected from the group consisting of S, O, NH, NMe, NEt, and NiPr; n is selected from the group consisting of any integer from 0 to 30; R 3 is selected from the group consisting of H, —(CH 2 ) c —H (where “c” is selected from the group consisting of any integer from 0 to 30), —CCl 3 , —CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 4 is selected from the group consisting of H, —(CH 2 ) d —H (wherein “d” is selected from the group consisting of any integer from 0 to 30), —CCl 3 , —CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 5 is a variable; 【Chemistry 67】 is the point of attachment to any of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, Formula G, Formula H, or Formula I; R 5 is Formula I 【Chemistry 68】 , formula ii 【Chemistry 69】 , formula iii 【Chemistry 70】 , formula iv 【Chemistry 71】 , formula v 【Chemical Formula 72】 , Formula vi 【Chemical 73】 , formula vii 【Chemical 74】 , formula viii 【Chemistry 75】 , formula ix 【Chemical 76】 , expression x 【Chemical Formula 77】 , formula xi 【Chemical 78】 , formula xii 【Chemical Formula 79】 , formula xiii 【Chemistry 80】 , formula xiv 【Chemistry 81】 , formula xv 【Chemistry 82】 and formula xvi 【Chemistry 83】 wherein: 【Chemistry 84】 is an attachment point for any of formula 1, formula 2, formula 3, formula 4, formula 5, formula 6, formula 7, formula 8, or formula 9; e is selected from the group consisting of any integer from 0 to 30; f is selected from the group consisting of any integer from 0 to 30; g is selected from the group consisting of any integer from 0 to 30; or L is 4-(hydroxymethyl)phenoxyacetyl ("HMPA"), 4-(hydroxymethyl)phenoxybutanoyl ("HMPB"), 4-(hydroxymethyl)benzoyl ("HMB"), 4-(mercaptomethyl)benzoyl ("MMB"), 4-(mercaptomethyl)phenoxyacetyl ("MMPA"), 4-(aminomethyl)phenoxyacetyl ("AMPA"), 4-(3,3-dimethyl-3-hydroxypropyl)phenoxyacetyl ("DMPPA"), 2-(4-(amino(2,4-dimethoxyphenyl)methyl)phenoxy)acetyl ("Rink Amide"), 4-((9-amino-9H-xanthen-3-yl)oxy)butanoyl ("xanthenyl"), 5-(5-amino-10,11-dihydro-5H-dibenzo[a,d][7]annulen-3-yl)pentanoyl ("TCA"), and 3-(4-(chloro(2-chlorophenyl)(phenyl)methyl)phenyl)propanoyl ("2-chlorotrityl").
7. Compound 1 (wherein n=2 or 9) 【Chemistry 85】 , compound 2 【Chemistry 86】 , compound 3 【Chemistry 87】 , Compound 4, where R=H, Me, Et, or iPr. 【Chemistry 88】 , Compound 5 (wherein n=0 or 2) 【Chemistry 89】 , Compound 6 (wherein n=0 or 2 and Y=O, NMe, NEt, or NiPr). 【Chemistry 90】 , Compound 7 (wherein n=0 or 2) 【Chemistry 91】 , Compound 8 (wherein n=0 or 2 and Y=O, NMe, NEt, or NiPr) 【Chemistry 92】 , compound 9 【Chemistry 93】 , Compound 10 (wherein n=0 or 2) 【Chemistry 94】 and compound 11, where n=0 or 2. 【Chemistry 95】 The composition of claim 6, selected from the group consisting of:
8. 1. A method for synthesizing a peptide, the method comprising: binding a first amino acid to an anchor molecule, the anchor molecule comprising a GAP moiety and a linker moiety, the first amino acid being attached to the linker moiety of the anchor molecule; forming a peptide bond between a second amino acid and the first amino acid; removing the anchor molecule from the first amino acid; Including, the anchor molecule further comprises a spacer moiety disposed between the GAP moiety and the linker moiety; The GAP component is Formula A 【Chemistry 96】 , formula B 【Chemistry 97】 , formula C 【Chemistry 98】 , formula D 【Chemistry 99】 , formula E 【Chemistry 100】 and formula F 【Chemistry 101】 wherein: A 1 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH 2 ) j -, where "j" is as defined below; A 2 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH 2 ) k -, where "k" is as defined below; A 3 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, and NPh; R 4 is selected from the group consisting of -(CH 2 ) m -H (where "m" is defined below), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 5 is selected from the group consisting of -(CH 2 ) p -Me (where "p" is defined below), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 6 is selected from the group consisting of Dpp, Dpop, and Dap, 【Chemistry 102】 But the following 【Chemistry 103】 is an abbreviation for 【Chemistry 104】 But the following 【Chemistry 105】 is an abbreviation for 【Chemistry 106】 But the following 【Chemistry 107】 is an abbreviation for; R 7 is selected from the group consisting of C y H (2y+1) (wherein "y" is defined below), OC y H (2y+1) (wherein "y" is defined below), NHC y H (2y+1) (wherein "y" is defined below), (2-ethyl)hexyl, and isooctyl; j, k, m, p, and y are separate numbers selected from the group consisting of any integer between 0 and 30; The linker moiety is Formula I 【Chemistry 108】 , formula II 【Chemistry 109】 , formula III 【Chemistry 110】 , formula IV 【Chemistry 111】 , formula V 【Chemistry 112】 , Formula VI 【Chemistry 113】 and Formula VII 【Chemistry 114】 wherein: X is selected from the group consisting of Y (defined below), -C(O)-, and -(CH2)a-, where "a" is defined below; Y is selected from the group consisting of S, NH, NMe, NEt, NBn, NPh, and O; R 1 is selected from the group consisting of -(CH 2 ) b -H (where "b" is defined below), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; R 2 is selected from the group consisting of -(CH 2 ) c -H (where "c" is defined below), -CCl 3 , -CF 3 , phenyl, isopropyl, tert-butyl, chlorophenyl, dichlorophenyl, methoxyphenyl, and dimethoxyphenyl; a, b, c, and n are separate numbers selected from the group consisting of any integer between 0 and 30; or The linker component may be 4-(hydroxymethyl)phenoxyacetyl ("HMPA"), 4-(hydroxymethyl)phenoxybutanoyl ("HMPB"), 4-(hydroxymethyl)benzoyl ("HMB"), 4-(mercaptomethyl)benzoyl ("MMB"), 4-(mercaptomethyl)phenoxyacetyl ("MMPA"), 4-(aminomethyl)phenoxyacetyl ("AMPA"), 4-(3,3-dimethyl-3-hydroxypropyl)phenoxyacetyl ("DMPPA"), 2-(4-(amino(2,4-dimethoxyphenyl)methyl)phenoxy)acetyl ("Rink Amide"), 4-((9-amino-9H-xanthen-3-yl)oxy)butanoyl ("xanthenyl"), 5-(5-amino-10,11-dihydro-5H-dibenzo[a,d][7]annulen-3-yl)pentanoyl ("TCA"), and 3-(4-(chloro(2-chlorophenyl)(phenyl)methyl)phenyl)propanoyl ("2-chlorotrityl"); The spacer moiety is Formula X 【Chemistry 115】 and formula Y 【Chemistry 116】 wherein: Z 1 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH 2 ) d -, where "d" is as defined below; Z 2 is selected from the group consisting of S, O, NH, NMe, NEt, NBn, NPh, -C(O)-, and -(CH 2 ) e -, where "e" is as defined below; d, e, f, g, h, i, and z are separate numbers selected from the group consisting of any integer between 0 and 30; R 3 is H, methyl, ethyl, propyl, isopropyl, benzyl, isobutyl, sec-butyl, tert-butyl, 2-(methylmercapto)ethyl, and the structures shown below: Formula 1 【Chemistry 117】 , Equation 2 【Chemistry 118】 , Equation 3 【Chemistry 119】 , Equation 4 【Chemistry 120】 , Equation 5 【Chemistry 121】 , Equation 6 【Chemistry 122】 , Equation 7 【Chemistry 123】 , Equation 8 【Chemical 124】 , Equation 9 【Chemistry 125】 , Equation 10 【Chemistry 126】 , Equation 11 【Chemistry 127】 , Equation 12 【Chemistry 128】 , Equation 13 【Chemistry 129】 , Equation 14 【Chemistry 130】 , Equation 15 【Chemistry 131】 , Equation 16 【Chemistry 132】 , Equation 17 【Chemistry 133】 , and Equation 18 【Chemistry 134】 The method of claim 1, wherein the
9. The method of claim 8, wherein the spacer component is a third amino acid.
10. The anchor molecule is Compound 1 (wherein n=2 or 9) 【Chemistry 135】 , compound 2 【Chemistry 136】 , compound 3 【Chemistry 137】 , Compound 4, where R=H, Me, Et, or iPr. 【Chemistry 138】 , Compound 5 (wherein n=0 or 2) 【Chemistry 139】 , Compound 6 (wherein n=0 or 2 and Y=O, NMe, NEt, or NiPr). 【Chemistry 140】 , Compound 7 (wherein n=0 or 2) 【Chemistry 141】 , Compound 8 (wherein n=0 or 2 and Y=O, NMe, NEt, or NiPr) 【Chemistry 142】 , compound 9 【Chemistry 143】 , Compound 10 (wherein n=0 or 2) 【Chemistry 144】 and compound 11, where n=0 or 2. 【Chemistry 145】 10. The method of claim 9, selected from the group consisting of:
11. 1. A method of forming a composition comprising a GAP anchor, the method comprising: Providing a GAP component; attaching the GAP moiety to a linker moiety; Including, The method further comprising linking said GAP moiety to a spacer moiety, wherein said GAP moiety is attached to said linker moiety via said spacer moiety.
12. binding said GAP moiety to said spacer moiety to form a Gap-spacer; Attaching the Gap-Spacer to the linker moiety; Further comprising: The spacer moiety is disposed between the GAP moiety and the linker moiety. The method of claim 11.
13. 【Catalogue 146】 The method of claim 11 , comprising the steps of:
14.
147. The method of claim 11 , comprising the steps of:
15. 1. A method for synthesizing a peptide, the method comprising: Attaching a GAP anchor to a first amino acid; forming a peptide bond between a second amino acid and the first amino acid; removing the GAP anchor from the first amino acid; Including, The GAP anchor is Compound 1 (wherein n=2 or 9) 【Chemistry 148】 , compound 2 【Chemistry 149】 , compound 3 【Chemistry 150】 , Compound 4, where R=H, Me, Et, or iPr. 【Chemistry 151】 , Compound 5 (wherein n=0 or 2) 【Chemistry 152】 , Compound 6 (wherein n=0 or 2 and Y=O, NMe, NEt, or NiPr). 【Chemistry 153】 , Compound 7 (wherein n=0 or 2) 【Chemistry 154】 , Compound 8 (wherein n=0 or 2 and Y=O, NMe, NEt, or NiPr) 【Chemistry 155】 , compound 9 【Chemistry 156】 , Compound 10 (wherein n=0 or 2) 【Chemistry 157】 and compound 11, where n=0 or 2. 【Chemistry 158】 Selected from the group consisting of: method.
